Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT for Oligo-residual NSCLC After PD-1/PD-L1 Inhibitors
NCT04767009Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2021
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Progression-free survival at 2 years. Started Jan 2021; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04767009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767009.